Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

156.19 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech ↗

October 05, 2026

Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.

Via The Motley Fool

Topics ETFs

Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals ↗

October 04, 2026

XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.

Via The Motley Fool

Topics ETFs

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? ↗

September 22, 2026

VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

Via The Motley Fool

Topics ETFs

Breakfast News: A Conversation With Ionis CEO ↗

August 22, 2026

Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.

Via The Motley Fool

Topics ETFs World Trade

IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy? ↗

August 20, 2026

XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield.

Via The Motley Fool

Topics ETFs

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets? ↗

August 19, 2026

XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗

August 18, 2026

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

Via The Motley Fool

Topics ETFs

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond? ↗

August 08, 2026

XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend.

Via The Motley Fool

Topics ETFs

Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗

August 03, 2026

XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite?

Via The Motley Fool

Topics ETFs

Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today ↗

July 13, 2026

State Street SPDR S&P Biotech ETF (NYSE:XBI) has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 12.55%. Currently, State Street...

Via Benzinga

Topics ETFs Stocks

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗

July 09, 2026

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.

Via The Motley Fool

Topics ETFs

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗

July 05, 2026

One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.

Via The Motley Fool

Topics ETFs

The Best Biotech Stocks to Buy in 2026 ↗

June 17, 2026

They have at least one thing in common: An exciting pipeline.

Via The Motley Fool

Topics ETFs

Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗

June 17, 2026

Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability.

Via The Motley Fool

Topics ETFs

3 Longevity ETFs to Buy and Hold (and Hold) ↗

June 08, 2026

The size of the longevity industry could roughly triple in the next decade, and these ETFs may help to provide access to a fast-growing space.

Via MarketBeat

Topics Artificial Intelligence ETFs

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗

June 05, 2026

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

Via The Motley Fool

Topics ETFs

VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗

May 28, 2026

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

Via The Motley Fool

Topics ETFs

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Via MarketBeat

Topics ETFs Intellectual Property

Small Caps Under Siege: Russell 2000 Enters Correction as Yields Surge

March 23, 2026

The small-cap segment of the U.S. stock market has officially entered correction territory, marking a stark reversal for a sector that many analysts expected to lead the "Great Rotation" of 2026. On...

Via MarketMinute

Topics Bonds ETFs Economy

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗

March 17, 2026

Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement.

Via Stocktwits

Topics ETFs

The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)

March 12, 2026

Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon...

Via Finterra

Topics ETFs Intellectual Property

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗

March 11, 2026

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.

Via Stocktwits

Topics ETFs

QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗

March 10, 2026

Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease...

Via Stocktwits

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗

March 10, 2026

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

Via Stocktwits

Topics Initial Public Offering

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗

March 09, 2026

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

Via Stocktwits

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗

March 09, 2026

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

Via Stocktwits

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Via Stocktwits

Why Did CRMD Stock Tumble Over 11% Today? ↗

March 05, 2026

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16.

Via Stocktwits

Topics Artificial Intelligence

Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗

March 05, 2026

BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.